Scheduling change for adrenaline product

Chris Brooker 12/01/2026

Intranasal adrenaline soon to become Pharmacist Only for treating anaphylaxis The Therapeutic Goods Administration has decided to downschedule intranasal preparations containing 2% or less of adrenaline to Pharmacist Only (Schedule 3) medicines. The TGA's Advisory Committee on Medicines Scheduling (ACMS) made the interim decision at its June 2025 meeting, publicly released in late December. The

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Scheduling change for adrenaline product

Previous Owner seeks Butler’s support to reopen pharmacy

Next Research Roundup

MENU

ajp.com.au

Previous Owner seeks Butler’s support to reopen pharmacy

Next Research Roundup

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.